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Drug therapy is a cornerstone in the clinical management of heart
failure (HF) and there is today consistent and strong evidence that
neurohormonal blockers reduce morbidity and mortality. Indeed,
the three pivotal clinical trials investigating the use of beta-blockers
in HF (CIBIS II, COPERNICUS, and MERIT-HF) showed an approxi-
mate 34% relative reduction in mortality.1 –3 ACE inhibitors (ACE-i)
were also shown to improve clinical outcomes in several landmark
trials, including CONSENSUS, SOLVD, and SAVE.4–6 More recently,
randomized trials have reported that angiotensin receptor antagonists
(ARBs) provide incremental benefit over background therapy with
ACE-i in HF7,8 and improve hard endpoints when used as a substitute
for ACE-i in intolerant patients.9 In spite of the documented benefits
of these drugs, there are still relevant clinical unmet needs in the
management of HF, even when optimal doses are used.
Implantable cardioverter defibrillators (ICDs) and cardiac resyn-
chronization therapy (CRT) have revolutionized the clinical manage-
ment of patients with HF, leading to impressive benefits onmortality
and hospitalizations when used in conjunction with optimized drug
therapy.10,11 Of note, patients treated with implantable devices for
cardiac rhythm management (CRM) are known to receive HF med-
ications more often and at higher doses than those not treated
with devices.12–14
In this issue of the Journal, Witt et al.15 report the long-term
follow-up of a large population of HF patients and show that device
therapy with CRT-D or CRT-P improves the use of ACE-i/ARBs
and increases the proportion of patients receiving target doses of
beta-blockers. Of note, follow-up data are extended to 4 years and
show that adherence to target doses remains high over the long
term, with a major impact on prognosis. These results extend and
strengthen findings from earlier studies.
In the IMPROVE HF,12 patients who were treated with CRM
devices received ACE-i or ARB therapy more often (and more fre-
quently at target doses) than did those not treated with devices.
Moreover, a favourable response to CRT has been reported to
be associated with higher use of beta-blockers and ACE-i/ARBs,
leading to a dose-dependent reduction in mortality.13 These results
are consistent with those observed by the MADIT-CRT investiga-
tors:14 in general, the greater the efficacyof CRT, the greater the like-
lihood that patients remain on ACE-i/ARBs and reduced treatment
with diuretics, that is time-dependently associated with an increased
risk of HF events or death.
The reasonswhyCRT-D andCRT-P are independently associated
with prescription, adherence and persistence of drug therapy at or
above target doses are presently unclear. However, by restoring
both mechanical and electrical synchronicity, CRT leads to an im-
provement in HF symptoms and blood pressure levels,16 most
likely resulting in higher tolerability to neurohormonal blockade.
Notably, Witt et al.15 report that only a small fraction of patients
received recommended target doses of ACE-i/ARBs and beta-
blockers. Indeed, although CRT allowed sufficient room for therapy
up-titration, only one-fifth to one-third of patients were on target
doses at 6 months. This is consistent with the findings from the
IMPROVE HF,12 showing that only !20% of eligible patients
treated with ICD, CRT-D, or CRT-P received beta-blockers and
one-third received ACE-i/ARBs at or above recommended target
doses.
The impressive reduction of hard endpoints obtained with ACE-i,
ARBs, and beta-blockers has been documented in randomized con-
trolled trials, a setting of tight clinical control in which target dose
therapy is pursued based on patients’ tolerance to up-titration.
Achievement of target doses of HF drugs in major trials ranges
from 58.6% for carvedilol in the COPERNICUS,17 to 64% for meto-
prolol in theMERIT-HF,18 and84% for valsartan in theVal-HeFT.19Of
note, as far as ARBs are concerned, clinical trials allowed therapeutic
drug doses considerably higher than those traditionally used in
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clinical practice. Indeed, in the Val-HeFT,19 the target daily dose of
valsartanwas 320 mg, and in theCHARM studies8,9,20,21 candesartan
was used at the target dose of 32 mg/day.
While international guidelines22 recommend tomake every effort
to achieve target doses shown to be effective in clinical trials, data
from real-life clinical practice indicate a less-than optimal use of HF
drugs that have amajor impact onprognosis. Indeed,whencompared
with trial patients, non-trial patients have farmore comorbidities that
limit tolerability of high doses of ACE-i and beta-blockers. Moreover,
patients’ response to therapy (and not tolerance to up-titration)
still drives the administration of HF drugs in many clinical settings.
Needless to say, failure to up-titrate neurohormonal blockers to
recommended doses provides less-than optimal modulation of neu-
rohormonal systems, exposingpatients to a greater riskof disease pro-
gression and mortality. Also, this behaviour affects morbidity and is
particularly relevant in patients implanted with ICDs. Indeed, sub-
optimal renin–angiotensin system and adrenergic blockade increase
the risk of appropriate ICD interventions.23–25
CRTanddrugup-titration inHFpatients are a clear-cut exampleof
effective therapy integration with synergistic effects. However, it
should be emphasized that, even in the setting of state-of-the-art
non-pharmacological treatment, target doses of ACE-i/ARBs and
beta-blockers are achieved in the real world at rates far lower than
reported in the pivotal trials and recommended by the guidelines.
There is still room to improve.
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